Thrivent Financial for Lutherans Increases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Thrivent Financial for Lutherans increased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 70.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 93,427 shares of the life sciences company’s stock after acquiring an additional 38,597 shares during the period. Thrivent Financial for Lutherans’ holdings in Integra LifeSciences were worth $2,119,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences in the third quarter worth $44,153,000. Charles Schwab Investment Management Inc. raised its position in shares of Integra LifeSciences by 10.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company’s stock worth $23,759,000 after purchasing an additional 103,291 shares during the period. Glenmede Trust Co. NA increased its position in Integra LifeSciences by 125.9% in the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock worth $13,224,000 after buying an additional 405,624 shares during the period. Systematic Financial Management LP grew its position in shares of Integra LifeSciences by 53.9% during the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock worth $11,115,000 after acquiring an additional 214,272 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Integra LifeSciences by 5.5% in the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock valued at $9,603,000 after purchasing an additional 22,000 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Trading Down 1.5 %

Shares of NASDAQ IART opened at $21.69 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $35.45. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -240.97, a P/E/G ratio of 0.73 and a beta of 1.23. The business has a fifty day simple moving average of $23.78 and a 200-day simple moving average of $22.15.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter in the prior year, the company earned $0.89 earnings per share. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.